Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
Targets |
KRas G12D; KRas G12V
|
---|---|
ln Vitro |
TUS-007 is toxic to cells expressing KRAS G12D/V and has a strong inhibitory effect on them [1]. Rather of impacting KRAS G12C, TUS-007 (100 μM; 72 h) indirectly affects the viability of low-RAS electrodes expressing KRAS G12D/V [1]. The fraction of annexin V-positive SW1990 cells in the bladder is increased by TUS-007 (20-160 μM; 72 h) [1].
|
ln Vivo |
TUS-007 (80 mg/kg i.p. or 160 mg/kg lateral; every 3 days for 21 days) suppresses KRAS G12V-driven tumors in vivo in the SW620-Luc xenograft model [ TUS -007 shows anti-tumor effect even in orthotopic xenograft models [1].
|
Cell Assay |
Apoptosis Analysis[1]
Cell Types: SW1990 Cell Tested Concentrations: 20 μM, 40 μM, 80 μM and 60 μM Incubation Duration: 72 hrs (hours) Experimental Results: Annexin V positive compared to cells treated with DMSO or RAS-SOS-NH2 The proportion of apoptotic SW1990 cells increased. |
Animal Protocol |
Animal/Disease Models: immunodeficient mice carrying SW620-Luc cells [1]
Doses: 80mg/kg or 160mg/kg Route of Administration: intraperitoneal (ip) injection or po (oral gavage); once every 3 days for 21 days Experimental Results: Dramatically attenuated tumor progression without affecting weight. |
References |
[1]. Imanishi S, et al. In vivo KRAS G12D/V degradation mediated by CANDDY using a modified proteasome inhibitor. bioRxiv, 2021: 2021.04. 23.441075.
|
Molecular Formula |
C44H54CL2N8O5
|
---|---|
Molecular Weight |
845.86
|
Exact Mass |
844.3594222
|
CAS # |
2227029-18-5
|
Related CAS # |
2227029-18-5
|
SMILES |
CC[C@@H](C)[C@@H](C(=O)NC1=CC2=C(C=C1)N=C(N2)CC3=CNC4=CC=CC=C43)NC(=O)CCCCCCNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)C5=C(C=CC(=C5)Cl)Cl
|
InChi Key |
LLBSNYUMQZVIBK-UKMLIFFGSA-N
|
InChi Code |
InChI=1S/C44H54Cl2N8O5/c1-5-27(4)41(44(59)50-30-16-18-35-36(23-30)52-38(51-35)21-28-24-48-34-13-10-9-12-31(28)34)54-39(55)14-8-6-7-11-19-47-43(58)37(20-26(2)3)53-40(56)25-49-42(57)32-22-29(45)15-17-33(32)46/h9-10,12-13,15-18,22-24,26-27,37,41,48H,5-8,11,14,19-21,25H2,1-4H3,(H,47,58)(H,49,57)(H,50,59)(H,51,52)(H,53,56)(H,54,55)/t27-,37+,41+/m1/s1
|
Chemical Name |
2,5-dichloro-N-[2-[[(2S)-1-[[7-[[(2S,3R)-1-[[2-(1H-indol-3-ylmethyl)-3H-benzimidazol-5-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-7-oxoheptyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]benzamide
|
Synonyms |
TUS-007
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1822 mL | 5.9111 mL | 11.8223 mL | |
5 mM | 0.2364 mL | 1.1822 mL | 2.3645 mL | |
10 mM | 0.1182 mL | 0.5911 mL | 1.1822 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.